DNA Double-Strand Break Repair Inhibitors: YU238259, A12B4C3 and DDRI-18 Overcome the Cisplatin Resistance in Human Ovarian Cancer Cells, but Not under Hypoxia Conditions

Cisplatin (CDDP) is the cornerstone of standard treatment for ovarian cancer. However, the resistance of ovarian cancer cells to CDDP leads to an inevitable recurrence. One of the strategies to overcome resistance to CDDP is the combined treatment of ovarian cancer with CDDP and etoposide (VP-16), a...

Descripción completa

Detalles Bibliográficos
Autores principales: Macieja, Anna, Gulbas, Izabela, Popławski, Tomasz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10605129/
https://www.ncbi.nlm.nih.gov/pubmed/37886943
http://dx.doi.org/10.3390/cimb45100500

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10605129/
https://www.ncbi.nlm.nih.gov/pubmed/37886943
http://dx.doi.org/10.3390/cimb45100500

Ejemplares similares